Last edition
News about "RadioMedix"
Sanofi and Partners Report Positive Phase 2 Results for AlphaMedix in Advanced GEP-NETs
AlphaMedix, which is developed by Orano Med and RadioMedix and now licensed to Sanofi, achieved all primary efficacy endpoints in the phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumours.
RadioMedix | 08/10/2025 | By Dineshwori | 414
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members